{
  "guideline" : {
    "objCls" : "Guideline",
    "@id" : "https://api.pharmgkb.org/data/guideline/PA166122686",
    "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
    "id" : "PA166122686",
    "name" : "Annotation of CPIC Guideline for fluorouracil and DPYD",
    "history" : [ {
      "id" : 1184511807,
      "date" : "2014-07-30T00:00:00-07:00",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1448604804,
      "date" : "2017-03-16T17:47:59.311-07:00",
      "description" : "Updated extended dosing guidelines",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1449140397,
      "date" : "2017-11-13T10:55:34.511-08:00",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1449154751,
      "date" : "2017-11-28T10:14:26.842-08:00",
      "type" : "update",
      "version" : 0
    } ],
    "recommendation" : true,
    "relatedChemicals" : [ {
      "objCls" : "Chemical",
      "@id" : "https://api.pharmgkb.org/data/chemical/PA128406956",
      "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
      "id" : "PA128406956",
      "name" : "fluorouracil",
      "version" : 14
    } ],
    "relatedGenes" : [ {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA145",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA145",
      "symbol" : "DPYD",
      "name" : "dihydropyrimidine dehydrogenase",
      "version" : 6905
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447982081,
      "externalLinks" : [ ],
      "html" : "<p>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50% and 25%-50%, respectively.</p>\n",
      "internalLinks" : [ ],
      "markdown" : "The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50% and 25%-50%, respectively.",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 9
    },
    "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447982080,
      "externalLinks" : [ "http://www.ncbi.nlm.nih.gov/pubmed/?term=24648345", "https://cpicpgx.org/", "https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf", "https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf", "https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/DPYD_preprint-supplement.pdf", "https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/DPYD_preprint.pdf", "https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx", "https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluorouracil_Drug_Resource_Mappings.xlsx", "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/", "https://www.ncbi.nlm.nih.gov/pubmed/26265346" ],
      "html" : "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-fluoropyrimidines-and-dpyd%2F\" target=\"_blank\">CPIC&reg; guideline for fluoropyrimidines and DPYD</a>.</p>\n<h3 id=\"november-2017-update\">November 2017 update</h3>\n<p><em>Advance online publication November 2017</em></p>\n<ul>\n<li>The 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. In particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. Additionally, dosing recommendations are now given in the context of <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F26265346\" target=\"_blank\">DPYD activity score</a>.</li>\n<li>Excerpts from the 2017 dosing guideline update:\n<ul>\n<li>&quot;The strength of the prescribing recommendations is based on the known impact of some variants (c.1905+1G&gt;A, c.1679T&gt;G, c.2846A&gt;T, c.1129– 5923C&gt;G) on DPD activity, the demonstrated relationship between DPD activity and 5-fluorouracil clearance, and between 5-fluorouracil exposure and its toxic effects.&quot;</li>\n<li>&quot;At the time of this writing, data on the possible role of DPYD genetic variation in 5-fluorouracil toxicity in pediatric patient populations is extremely scarce; however, there is no evidence to suggest that 5-fluorouracil pharmacokinetics differ from adult patients, and thus no evidence that DPYD variants would affect 5-fluorouracil metabolism differently in children.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Ffluoropyrimidines%2F2017%2FDPYD_preprint.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Ffluoropyrimidines%2F2017%2FDPYD_preprint-supplement.pdf\" target=\"_blank\">2017 supplement</a></li>\n<li><a href=\"https://www.pharmgkb.org/page/dpydRefMaterials\">Gene-specific Information Tables for DPYD</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Ffluoropyrimidines%2FFluorouracil_Drug_Resource_Mappings.xlsx\" target=\"_blank\">5-Fluorouracil drug resource mapping</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Ffluoropyrimidines%2FFluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\" target=\"_blank\">Fluoropyrimidines pre- and post-test alerts and flow chart</a></li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype\">Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.</h3>\n<p><em>Adapted from Tables 1 and 2 of the 2017 guideline manuscript.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Likely Phenotype</th><th>Activity Score<sup>a</sup></th><th>Genotypes<sup>b</sup></th><th>Examples of genotypes<sup>c</sup></th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations<sup>d</sup></th></tr>\n</thead>\n<tbody>\n<tr><td><em>DPYD</em> Normal Metabolizer</td><td>2</td><td>An individual carrying two normal alleles</td><td>c.[=];[=], c.[85T&gt;C<sup>e</sup>];[=], c.[1627A&gt;G<sup>f</sup>];[=]</td><td>Normal DPD activity and “normal” risk for fluoropyrimidine toxicity</td><td>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration</td><td>Strong</td></tr>\n<tr><td><em>DPYD</em> Intermediate Metabolizer</td><td>1 or 1.5</td><td>An individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles</td><td>c.[1905+1G&gt;A<sup>g</sup>];[=], c.[1679T&gt;G<sup>h</sup>];[=], c.[2846A&gt;T<sup>i</sup>];[=]; c.[1129–5923C&gt;G<sup>j</sup>];[=]; c.[1129–5923C&gt;G];[1129–5923C&gt;G]; c.[2846A&gt;T];[2846A&gt;T]</td><td>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Reduce starting dose based on activity score followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).<br/>Activity score 1: Reduce dose by 50%.<br/>Activity score 1.5: Reduce dose by 25% to 50%</td><td>Activity score 1: Strong.<br/>Activity score 1.5: Moderate</td></tr>\n<tr><td><em>DPYD</em> Poor Metabolizer</td><td>0 or 0.5</td><td>An individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele</td><td>c.[1905+1G&gt;A];[1905+1G&gt;A], c.[1679T&gt;G];[1679T&gt;G], c.[1905+1G&gt;A];[2846A&gt;T] c.[1905+1G&gt;A];[1129-5923C&gt;G]</td><td>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose<sup>k</sup> with early therapeutic drug monitoring.<sup>l</sup><br/>Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><sup>a</sup> Calculated as the sum of the two lowest individual variant activity scores. See main guideline for further information.<br />\n<sup>b</sup> Allele definitions, assignment of allele function and references can be found using the <a href=\"https://www.pharmgkb.org/page/dpydRefMaterials\">DPYD Allele Functionality Table</a>.<br />\n<sup>c</sup> HGVS nomenclature using the reference sequence NM_000110.3.<br />\n<sup>d</sup> Rating scheme described in the <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Ffluoropyrimidines%2F2013%2F23988873-supplement.pdf\" target=\"_blank\">Supplement</a>.<br />\n<sup>e</sup> Also known as <a href=\"/variant/PA166153648\">rs1801265</a> or DPYD*9A<br />\n<sup>f</sup> Also known as <a href=\"/variant/PA166153646\">rs1801159</a> or DPYD*5<br />\n<sup>g</sup> Also known as <a href=\"/variant/PA166153760\">rs3918290</a> or DPYD*2A<br />\n<sup>h</sup> Also known as <a href=\"/variant/PA166153888\">rs55886062</a> or DPYD*13<br />\n<sup>i</sup> Also known as <a href=\"/variant/PA166153895\">rs67376798</a><br />\n<sup>j</sup> Also known as <a href=\"/variant/PA166153906\">rs75017182</a>. Likely HapB3 causal variant. See <a href=\"https://www.pharmgkb.org/page/dpydRefMaterials\">DPYD Allele Functionality Table</a> for other HapB3 proxy SNPs.<br />\n<sup>k</sup> If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of &lt;25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.<br />\n<sup>l</sup> Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high.</p>\n<h3 id=\"may-2014-update-on-pharmgkb\">May 2014 Update on PharmGKB</h3>\n<ul>\n<li>The CPIC authors recommend that the <em>DPYD*4</em>, <em>*5</em>, <em>*6</em> and <em>*9A</em> alleles be categorized as &quot;normal&quot; activity, in part based upon the recent publication <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F%3Fterm%3D24648345\" target=\"_blank\">Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity</a>.</li>\n</ul>\n<h3 id=\"december-2013-publication\">December 2013 Publication</h3>\n<p><em>Advance online publication October 2013.</em></p>\n<ul>\n<li>Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in <em>Clinical Pharmacology and Therapeutics</em> by the Clinical Pharmacogenetics Implementation Consortium <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2F\" target=\"_blank\">(CPIC)</a>.</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Ffluoropyrimidines%2F2013%2F23988873.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org%2Fcontent%2Fguideline%2Fpublication%2Ffluoropyrimidines%2F2013%2F23988873-supplement.pdf\" target=\"_blank\">2013 supplement</a></li>\n</ul>\n</li>\n</ul>\n",
      "internalLinks" : [ "/page/dpydRefMaterials", "/variant/PA166153646", "/variant/PA166153648", "/variant/PA166153760", "/variant/PA166153888", "/variant/PA166153895", "/variant/PA166153906" ],
      "markdown" : "This annotation is based on the [CPIC&reg; guideline for fluoropyrimidines and DPYD](https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).\n\n## November 2017 update\n\n_Advance online publication November 2017_\n- The 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. In particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. Additionally, dosing recommendations are now given in the context of [DPYD activity score](https://www.ncbi.nlm.nih.gov/pubmed/26265346).\n- Excerpts from the 2017 dosing guideline update:\n    - \"The strength of the prescribing recommendations is based on the known impact of some variants (c.1905+1G>A, c.1679T>G, c.2846A>T, c.1129– 5923C>G) on DPD activity, the demonstrated relationship between DPD activity and 5-fluorouracil clearance, and between 5-fluorouracil exposure and its toxic effects.\"\n    - \"At the time of this writing, data on the possible role of DPYD genetic variation in 5-fluorouracil toxicity in pediatric patient populations is extremely scarce; however, there is no evidence to suggest that 5-fluorouracil pharmacokinetics differ from adult patients, and thus no evidence that DPYD variants would affect 5-fluorouracil metabolism differently in children.\" \n- Download and read: \n  - [Clinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update](https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/DPYD_preprint.pdf)\n  - [2017 supplement](https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/DPYD_preprint-supplement.pdf)\n  - [Gene-specific Information Tables for DPYD](https://www.pharmgkb.org/page/dpydRefMaterials)\n  - [5-Fluorouracil drug resource mapping](https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluorouracil_Drug_Resource_Mappings.xlsx)\n  - [Fluoropyrimidines pre- and post-test alerts and flow chart](https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx)\n\n##  Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.\n\n_Adapted from Tables 1 and 2 of the 2017 guideline manuscript._\n\n| Likely Phenotype | Activity Score^a^ | Genotypes^b^ | Examples of genotypes^c^| Implications | Dosing recommendations | Classification of recommendations^d^ |\n| --- | --- | --- | --- | --- | --- | --- |\n| _DPYD_ Normal Metabolizer | 2 | An individual carrying two normal alleles | c.\\[=];\\[=], c.\\[85T>C^e^];\\[=], c.\\[1627A>G^f^];\\[=] | Normal DPD activity and “normal” risk for fluoropyrimidine toxicity| Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration | Strong |\n| _DPYD_ Intermediate Metabolizer | 1 or 1.5 | An individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles | c.\\[1905+1G>A^g^];\\[=], c.\\[1679T>G^h^];\\[=], c.\\[2846A>T^i^];\\[=]; c.\\[1129–5923C>G^j^];\\[=]; c.\\[1129–5923C>G];\\[1129–5923C>G]; c.\\[2846A>T];\\[2846A>T] | Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs | Reduce starting dose based on activity score followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). // Activity score 1: Reduce dose by 50%. // Activity score 1.5: Reduce dose by 25% to 50% | Activity score 1: Strong. // Activity score 1.5: Moderate |\n| _DPYD_ Poor Metabolizer | 0 or 0.5 | An individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele | c.\\[1905+1G>A];\\[1905+1G>A], c.\\[1679T>G];\\[1679T>G], c.\\[1905+1G>A];\\[2846A>T] c.\\[1905+1G>A];\\[1129-5923C>G] | Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs | Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose^k^ with early therapeutic drug monitoring.^l^ // Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. | Strong |\n\n^a^ Calculated as the sum of the two lowest individual variant activity scores. See main guideline for further information.  \n^b^ Allele definitions, assignment of allele function and references can be found using the [DPYD Allele Functionality Table](https://www.pharmgkb.org/page/dpydRefMaterials).  \n^c^ HGVS nomenclature using the reference sequence NM_000110.3.  \n^d^ Rating scheme described in the [Supplement](https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf).  \n^e^ Also known as [rs1801265](/variant/PA166153648) or DPYD*9A  \n^f^ Also known as [rs1801159](/variant/PA166153646) or DPYD*5  \n^g^ Also known as [rs3918290](/variant/PA166153760) or DPYD*2A  \n^h^ Also known as [rs55886062](/variant/PA166153888) or DPYD*13  \n^i^ Also known as [rs67376798](/variant/PA166153895)  \n^j^ Also known as [rs75017182](/variant/PA166153906). Likely HapB3 causal variant. See [DPYD Allele Functionality Table](https://www.pharmgkb.org/page/dpydRefMaterials) for other HapB3 proxy SNPs.  \n^k^ If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.  \n^l^ Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high.\n\n##  May 2014 Update on PharmGKB\n- The CPIC authors recommend that the _DPYD*4_, _*5_, _*6_ and _*9A_ alleles be categorized as \"normal\" activity, in part based upon the recent publication [Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity](http://www.ncbi.nlm.nih.gov/pubmed/?term=24648345). \n\n## December 2013 Publication\n\n_Advance online publication October 2013._\n- Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in _Clinical Pharmacology and Therapeutics_ by the Clinical Pharmacogenetics Implementation Consortium [(CPIC)](https://cpicpgx.org/).\n- Download and read:\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing](https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf)\n  - [2013 supplement](https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf)",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 12
    },
    "version" : 26,
    "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983463,"name":"Based on a CPIC dosing guideline","resource":"Web Resource","sameAs":"https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-fluoropyrimidines-and-dpyd%2F","xrefId":"https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"} ]
  },
  "annotationGroups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128875",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128875",
    "name" : "Poor Metabolizer with Activity Score of 0.5",
    "annotations" : [ {
      "id" : 1446441845,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986746,
        "externalLinks" : [ ],
        "html" : "<p>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1448589771,
      "history" : [ {
        "id" : 1448589769,
        "date" : "2017-02-06T10:36:34.086-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589770,
        "externalLinks" : [ ],
        "html" : "<p>Poor Metabolizer. Activity Score = 0.5.</p>\n<p><em>Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Poor Metabolizer. Activity Score = 0.5.\n\n_Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 2
    }, {
      "id" : 1446441861,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986748,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one no function plus one decreased function allele.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one no function plus one decreased function allele.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 2
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1446441877,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986750,
        "externalLinks" : [ ],
        "html" : "<p>Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose* with early therapeutic drug monitoring**.</p>\n<p><em>*If available, a phenotyping test (see guideline for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of &lt;25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.</em></p>\n<p><em>**Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose* with early therapeutic drug monitoring**. \n\n_*If available, a phenotyping test (see guideline for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance._ \n\n_**Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 8
    } ],
    "genePhenotypes" : [ "DPYD:Decreased Function/No Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166122686",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166122686",
      "name" : "Annotation of CPIC Guideline for fluorouracil and DPYD",
      "version" : 26
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 12
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128876",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128876",
    "name" : "Intermediate Metabolizer with Activity Score of 1",
    "annotations" : [ {
      "id" : 1446441893,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986752,
        "externalLinks" : [ ],
        "html" : "<p>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 8
    }, {
      "id" : 1448589779,
      "history" : [ {
        "id" : 1448589777,
        "date" : "2017-02-06T10:43:17.665-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589778,
        "externalLinks" : [ ],
        "html" : "<p>Intermediate Metabolizer. Activity Score = 1.</p>\n<p><em>Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Intermediate Metabolizer. Activity Score = 1.\n\n_Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 2
    }, {
      "id" : 1446441911,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986754,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one normal function allele plus one no function allele, or an individual carrying two decreased function alleles.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one normal function allele plus one no function allele, or an individual carrying two decreased function alleles.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 2
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1446441928,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986756,
        "externalLinks" : [ ],
        "html" : "<p>Reduce starting dose by 50% followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or therapeutic drug monitoring (if available).</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Reduce starting dose by 50% followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or therapeutic drug monitoring (if available).",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 8
    } ],
    "genePhenotypes" : [ "DPYD:Decreased Function/Decreased Function", "DPYD:No Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166122686",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166122686",
      "name" : "Annotation of CPIC Guideline for fluorouracil and DPYD",
      "version" : 26
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 13
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128877",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128877",
    "name" : "Normal Metabolizer (Activity Score=2)",
    "annotations" : [ {
      "id" : 1446441952,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986759,
        "externalLinks" : [ ],
        "html" : "<p>Normal DPD activity and &quot;normal&quot; risk for fluoropyrimidine toxicity.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1448589775,
      "history" : [ {
        "id" : 1448589773,
        "date" : "2017-02-06T10:40:03.209-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1448589774,
        "externalLinks" : [ ],
        "html" : "<p>Normal Metabolizer. Activity score = 2.</p>\n<p><em>Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Normal Metabolizer. Activity score = 2.\n\n_Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 2
    }, {
      "id" : 1446441966,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986760,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying two normal function alleles.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying two normal function alleles.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 2
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 10
    }, {
      "id" : 1446441989,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986762,
        "externalLinks" : [ ],
        "html" : "<p>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 1
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 8
    } ],
    "genePhenotypes" : [ "DPYD:Normal Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166122686",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166122686",
      "name" : "Annotation of CPIC Guideline for fluorouracil and DPYD",
      "version" : 26
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 12
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166171148",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166171148",
    "name" : "Intermediate Metabolizer with Activity Score of 1.5",
    "annotations" : [ {
      "id" : 1449146497,
      "history" : [ {
        "id" : 1449146495,
        "date" : "2017-11-14T10:20:20.374-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146496,
        "externalLinks" : [ ],
        "html" : "<p>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1449146500,
      "history" : [ {
        "id" : 1449146498,
        "date" : "2017-11-14T10:20:32.807-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146499,
        "externalLinks" : [ ],
        "html" : "<p>Intermediate Metabolizer. Activity Score = 1.5.</p>\n<p><em>Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Intermediate Metabolizer. Activity Score = 1.5.\n\n_Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1449146503,
      "history" : [ {
        "id" : 1449146501,
        "date" : "2017-11-14T10:20:41.683-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146502,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying one normal function allele plus one decreased function allele.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying one normal function allele plus one decreased function allele.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1449146507,
      "history" : [ {
        "id" : 1449146505,
        "date" : "2017-11-14T10:21:23.693-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146506,
        "externalLinks" : [ ],
        "html" : "<p>Reduce starting dose by 25% to 50% followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or therapeutic drug monitoring (if available).</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Reduce starting dose by 25% to 50% followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or therapeutic drug monitoring (if available).",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 0
    } ],
    "genePhenotypes" : [ "DPYD:Decreased Function/Normal Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166122686",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166122686",
      "name" : "Annotation of CPIC Guideline for fluorouracil and DPYD",
      "version" : 26
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501931",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501931,
      "resource" : "Guideline Strength",
      "term" : "Moderate",
      "termId" : "guidelineStrength:981501931",
      "version" : 0
    },
    "version" : 1
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166171147",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166171147",
    "name" : "Poor Metabolizer with Activity Score of 0",
    "annotations" : [ {
      "id" : 1449146511,
      "history" : [ {
        "id" : 1449146509,
        "date" : "2017-11-14T10:22:00.612-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146510,
        "externalLinks" : [ ],
        "html" : "<p>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1449146514,
      "history" : [ {
        "id" : 1449146512,
        "date" : "2017-11-14T10:22:12.198-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146513,
        "externalLinks" : [ ],
        "html" : "<p>Poor Metabolizer. Activity Score = 0.</p>\n<p><em>Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity.</em></p>\n",
        "internalLinks" : [ ],
        "markdown" : "Poor Metabolizer. Activity Score = 0.\n\n_Activity Score is calculated as the sum of the two lowest individual variant activity scores. Variant activity scores are 1 for normal function, 0.5 for decreased function, and 0 for no function or minimal activity._",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501926",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501926,
        "description" : "Likely phenotype of metabolizer status",
        "resource" : "Guideline Tags",
        "term" : "Metabolizer Status",
        "termId" : "guidelineTags:981501926",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1449146517,
      "history" : [ {
        "id" : 1449146515,
        "date" : "2017-11-14T10:22:21.545-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146516,
        "externalLinks" : [ ],
        "html" : "<p>An individual carrying two no function alleles.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "An individual carrying two no function alleles.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 0
    }, {
      "id" : 1449146520,
      "history" : [ {
        "id" : 1449146518,
        "date" : "2017-11-14T10:22:35.760-08:00",
        "type" : "create",
        "version" : 0
      } ],
      "markdown" : {
        "id" : 1449146519,
        "externalLinks" : [ ],
        "html" : "<p>Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 0
    } ],
    "genePhenotypes" : [ "DPYD:No Function/No Function" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166122686",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166122686",
      "name" : "Annotation of CPIC Guideline for fluorouracil and DPYD",
      "version" : 26
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 1
  } ],
  "genePhenotypes" : {
    "DPYD" : {
      "Any normal function variant or no variant detected" : "Normal Function",
      "c.295_298delTCAT" : "No Function",
      "c.557A>G" : "Decreased Function",
      "c.703C>T" : "No Function",
      "c.1129-5923C>G" : "Decreased Function",
      "c.1156G>T" : "No Function",
      "c.1679T>G" : "No Function",
      "c.1898delC" : "No Function",
      "c.1905+1G>A" : "No Function",
      "c.2846A>T" : "Decreased Function",
      "c.2983G>T" : "No Function"
    }
  },
  "citations" : [ {
    "@id" : "https://api.pharmgkb.org/data/literature/29152729",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 15099812,
    "resourceId" : "29152729",
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update",
    "authors" : [ "Amstutz Ursula", "Henricks Linda M", "Offer Steven M", "Barbarino Julia", "Schellens Jan H M", "Swen Jesse J", "Klein Teri E", "McLeod Howard L", "Caudle Kelly E", "Diasio Robert B", "Schwab Matthias" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 11,
    "nonHuman" : false,
    "pubDate" : "2017-11-01T00:00:00-07:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/29152729",
    "sentences" : [ ],
    "summary" : "The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC(®) ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).",
    "type" : "article",
    "version" : 0,
    "year" : 2017
  }, {
    "@id" : "https://api.pharmgkb.org/data/literature/23988873",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 15062135,
    "resourceId" : "23988873",
    "title" : "Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing",
    "authors" : [ "Caudle Kelly E", "Thorn Caroline F", "Klein Teri E", "Swen Jesse J", "McLeod Howard L", "Diasio Robert B", "Schwab Matthias" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 8,
    "nonHuman" : false,
    "pubDate" : "2013-08-01T00:00:00-07:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/23988873",
    "sentences" : [ {
      "text" : "Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing",
      "location" : "title",
      "id" : 15062136,
      "sentenceIndex" : 0
    }, {
      "text" : "The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers.",
      "location" : "abstract",
      "id" : 15062137,
      "sentenceIndex" : 1
    }, {
      "text" : "Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD encoded by the DPYD gene) and reduced or absent activity of this enzyme can result in severe and sometimes fatal toxicity.",
      "location" : "abstract",
      "id" : 15062138,
      "sentenceIndex" : 2
    }, {
      "text" : "We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at www.pharmgkb.org).Clinical Pharmacology & Therapeutics (2013); accepted article preview online 29 August 2013; doi:10.1038/clpt.2013.172.",
      "location" : "abstract",
      "id" : 15062139,
      "sentenceIndex" : 3
    } ],
    "summary" : "The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD encoded by the DPYD gene) and reduced or absent activity of this enzyme can result in severe and sometimes fatal toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at www.pharmgkb.org).Clinical Pharmacology & Therapeutics (2013); accepted article preview online 29 August 2013; doi:10.1038/clpt.2013.172.",
    "type" : "article",
    "version" : 1,
    "year" : 2013
  } ]
}